Who is sponsoring NCT03392792?

NCT03392792 is sponsored by Assiut University.

What drugs are being tested in NCT03392792?

Interventions in NCT03392792: tissue plasminogen activator, thrombectomy.

Is NCT03392792 still recruiting?

NCT03392792 is currently status unknown. Last updated 8 January 2018.

Last reviewed 2018-01-08 · How we verify

NCT03392792

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Regisry of the Stroke Patients in Assiut University Hospital

Status unknown NA Last updated 8 January 2018

What this trial tests

NA trial testing tissue plasminogen activator in All Patients With Ischemic Cerebrovascular Stroke Aged ≥18 Years of Both Sex in 1 participant. Status unknown.

Timeline

30 December 2018

Primary endpoint
30 December 2018

30 December 2018

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	30 December 2018
Primary completion	30 December 2018
Estimated completion	30 December 2018

Drugs / interventions tested

tissue plasminogen activator — full drug profile →
thrombectomy

Conditions studied

All Patients With Ischemic Cerebrovascular Stroke Aged ≥18 Years of Both Sex — all drugs for All Patients With Ischemic Cerebrovascular Stroke Aged ≥18 Years of Both Sex →

Sponsor

Assiut University

Who can join

18 and older, any sex, with All Patients With Ischemic Cerebrovascular Stroke Aged ≥18 Years of Both Sex. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

• Aim of the work To register all type of acute stroke admitted in Assiut university Hospital and assessment of their risk factor, morbidity and Mortality

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of tissue plasminogen activator

Trials testing the same drug.

NCT03335839 — Adjunctive, Low-dose tPA in Primary PCI for STEMI · Phase 3 · completed

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03392792 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 8 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03392792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing